American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 349-353 , September 2007

Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: An Overview

  • Daniel E. Weiner, MD, MS

      Affiliations

    • Corresponding Author InformationAddress correspondence to Daniel E. Weiner, MD, MS, Division of Nephrology, Tufts-New England Medical Center Box #391, 750 Washington St, Boston, MA 02111.
    • ,
  • Andrew S. Levey, MD

References 

  1. Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernan MA. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA. 2007;297:1667–1674
  2. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  3. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  4. US Food and Drug Administration. Public Health Advisory: Erythropoiesis-stimulating agents (ESAs). US Food and Drug Administration; 2007;March 14
  5. Coyne DW. Use of epoetin in chronic renal failure. JAMA. 2007;297:1713–1716
  6. Beusterien KM, Nissenson AR, Port FK, Kelly M, Steinwald B, Ware JE. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol. 1996;7:763–773
  7. Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin (Cooperative Multicenter EPO Clinical Trial Group). JAMA. 1990;263:825–830
  8. Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis. 1995;25:548–554
  9. Collins AJ, Li S, St Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001;12:2465–2473
  10. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1990;10:610–619
  11. McClellan WM, Helgerson SD, Frederick PR, Wish JB, McMullan M. Implementing the Health Care Quality Improvement Program in the Medicare ESRD Program: a new era of quality improvement in ESRD. Adv Ren Replace Ther. 1995;2:89–94
  12. Rocco MV, Frankenfield DL, Hopson SD, McClellan WM. Relationship between clinical performance measures and outcomes among patients receiving long-term hemodialysis. Ann Intern Med. 2006;145:512–519
  13. Parfrey PS. In the literature: on clinical performance measures and outcomes among hemodialysis patients. Am J Kidney Dis. 2007;49:352–355
  14. Steinbrook R. Medicare and erythropoietin. N Engl J Med. 2007;356:4–6
  15. Rettig RA, Levinsky NG. Committee for the Study of the Medicare End-Stage Renal Disease Program: Kidney Failure and the Federal Government. Washington, DC: Committee for the Study of the Medicare End-Stage Renal Disease Program, Division of Health Care Services; 1991;
  16. Lockridge RS. The direction of end-stage renal disease reimbursement in the United States. Semin Dial. 2004;17:125–130
  17. Sisk JE, Gianfrancesco FD, Coster JM. Recombinant erythropoietin and Medicare payment. JAMA. 1991;266:247–252
  18. de Lissovoy G, Powe NR, Griffiths RI, et al. The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients. Med Care. 1994;32:130–140
  19. United States Department of Health and Human Services Office of the Inspector GeneralMedicare reimbursement for Existing End-Stage Renal Disease Drugs. Available at: http://www.medicarerxguide.com/MDRG/2005/oei-03-04-00120.pdf. Accessed July 17, 2007
  20. National Kidney Foundation. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis. 1997;30(suppl 3):S192–S240
  21. National Kidney Foundation. K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis. 2001;37(suppl 1):S182–S238
  22. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin Level Variability: Associations with Comorbidity, Intercurrent Events, and Hospitalizations. Clin J Am Soc Nephrol. 2006;1:1205–1210
  23. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68:1337–1343
  24. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis. 2006;47(suppl 3):S16–S85
  25. National Kidney Foundation. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target. Am J Kidney Dis. 2007;50:471–530
  26. Collins AJ, Ebben JP, Gilbertson DT. EPO adjustments in patients with elevated hemoglobin levels: provider practice patterns compared with recommended practice guidelines. Am J Kidney Dis. 2007;49:135–142

PII: S0272-6386(07)01033-5

doi: 10.1053/j.ajkd.2007.07.003

American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 349-353 , September 2007

Article Tools

* Image Usage & Resolution